Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

3.48
-0.1500-4.13%
Post-market: 3.540.0600+1.72%19:30 EDT
Volume:1.19M
Turnover:4.16M
Market Cap:382.02M
PE:-20.47
High:3.63
Open:3.62
Low:3.44
Close:3.63
52wk High:5.45
52wk Low:2.53
Shares:109.77M
Float Shares:84.96M
Volume Ratio:1.25
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-2.0100
ROE:-4.77%
ROA:-28.42%
PB:1.04
PE(LYR):-1.73

Loading ...

Assessing Rocket Pharmaceuticals (RCKT) Valuation After Accelerated FDA Approval Of KRESLADI

Simply Wall St.
·
Mar 30

Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

TIPRANKS
·
Mar 28

Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 28

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

TIPRANKS
·
Mar 28

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

TIPRANKS
·
Mar 28

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Reuters
·
Mar 27

Rocket Pharmaceuticals Shares Reverse Premarket Gains, Last Down 10%

THOMSON REUTERS
·
Mar 27

Rocket Pharma Exec Says Co in Active Discussions and Engaging With External Parties Regarding the Sale of the Priority Review Voucher

THOMSON REUTERS
·
Mar 27

Rocket Pharma Exec Says Co Has Been Engaging With Payers to Ensure Reimbursement Ahead of Launch - Conf Call

THOMSON REUTERS
·
Mar 27

Rocket Pharma Exec Says Co Anticipates Commercial Availability of Kresladi in Q4 of 2026 - Exec Says

THOMSON REUTERS
·
Mar 27

Rocket Pharmaceuticals Shares up 10.2% Premarket After US FDA Approve Co's Therapy for Deadly Childhood Disorder

THOMSON REUTERS
·
Mar 27

Top Premarket Gainers

MT Newswires Live
·
Mar 27

Rocket Pharmaceuticals gains FDA accelerated approval for KRESLADI in severe pediatric LAD-I; FDA grants rare pediatric disease priority review voucher

Reuters
·
Mar 27

Rocket Pharmaceuticals Announces FDA Approval of Kresladi™ for Pediatric Patients With Severe Leukocyte Adhesion Deficiency-I (Lad-I)

THOMSON REUTERS
·
Mar 27

Rocket Pharmaceuticals announces 2026 annual stockholders meeting

Reuters
·
Mar 25

Rocket Pharma Advances BAG3 Heart Disease Study, Bolstering Long-Term Gene Therapy Story

TIPRANKS
·
Mar 21

Rocket Pharmaceuticals Inc - Enters Sales Agreement With Cantor Fitzgerald & Co. for Atm Offering up to $100 Mln - SEC Filing

THOMSON REUTERS
·
Mar 11

Rocket Pharmaceuticals signs equity distribution deal for USD 100 million at-the-market offering

Reuters
·
Mar 11